FDA Sends J&J a Warning Letter for Clinical Trial Failures


Johnson and Johnson received a Warning Letter from FDA for their failure to properly supervise clinical trials. The letter, issued by the Center for Drug Evaluation and Research’s Division of Scientific Investigations (DSI) on 10 August 2009, was addressed to the J&J Pharmaceutical Research & Development group in Raritan, NJ and cited failures for sponsor responsibilities.FDA Warning Letter

It is pretty rare for a pharmaceutical company to get a Warning Letter for clinical trial sponsor activities (called “Sponsor-Monitor” inspections). Approximately 10 were issued in fiscal year 2008 and most of those were to small medical device firms or to sponsor-investigators, physicians who both sponsor and conduct a clinical trial. The last major Warning Letter to a large pharmaceutical company was to Sanofi Aventis in October 2007 for research misconduct in the Aventis clinical trials for the drug Ketek. So DSI sending a Warning Letter to an industry giant like J&J is a pretty big deal. It certainly is in keeping with Commissioner Margaret Hamburg’s new emphasis on enforcement (see previous posts).

The Warning Letter cites J&J for “Failure to ensure proper monitoring of the clinical investigations.” This is the most common citation for a Sponsor-Monitor Warning Letter and has been for many years. DSI charges that J&J’s monitors failed to identify that drug infusions were given at the same identical time to multiple subjects. The drug is administered by an IV infusion and the source documents were contradictory and should have alerted the monitors of possible fraud. The Warning Letter cites detailed violations for study drug administration, shipments, and the necessary refrigerated storage.

The lengthy Warning Letter also cites J&J for “Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols” and “Failure to secure investigator compliance.” These are also common violations for a Sponsor-Monitor Warning Letter. You can read the letter for yourself on the Blogroll: 1 FDA Warning Letter to J&J.

It will be interesting to see if the new enforcement climate will deal new Warning Letters to pharmaceutical and medical device sponsors or if this was an aberration. The one thing that it has in common with the Sanofi Aventis Warning Letter is that there is a suggestion of fraud. There are many things other than fraud that can go wrong in a clinical trial. Is this FDA’s standard?

I am attaching an article that I wrote for RAPS Regulatory Focus magazine in July 2008. It deals with the topic of quality systems in monitoring clinical trials.

July 08_Anderson_RAPS Focus_Monitoring

Update: FDA also sends a Warning Letter to the CRO involved, ICON Clinical Research. Read the Post:

https://carl1anderson.wordpress.com/2009/12/08/fda-hits-icon-with-warning-letter-for-j-j-studies/

GxP Perspectives LinkedIn Group

6 Responses to FDA Sends J&J a Warning Letter for Clinical Trial Failures

  1. AFenty says:

    who conducted the study on behalf of JnJ?
    And were they cited, sent a warning letter?

    • Carl's Blog on FDA Stuff says:

      I don’t know. I assume it was an ex-US trial and that is why we don’t know the CRO or investigator. FDA does not appear to be sending Warning Letters to foreign firms at this time. To find out if there was a FDA 483 would take a Freedom of Information Act request.

  2. […] Warning Letter for J & J StudiesClinical Trial Compliance & Checklists: The Right Approach?FDA Sends J&J a Warning Letter for clinical trial failures as a sponsor Analysis of Recent FDA Warning Letters to IRBsArticles by CarlFDA Panel discusses "Artificial […]

  3. […] Warning Letter for J & J StudiesClinical Trial Compliance & Checklists: The Right Approach?FDA Sends J&J a Warning Letter for clinical trial failures as a sponsor Analysis of Recent FDA Warning Letters to IRBsArticles by CarlFDA Panel discusses "Artificial […]

  4. Theresa Walker says:

    I am wondering what the FDA regs and Guidances are for contracted writers of the CMC section of the IND? I know of a company who is contracting the writing of the CMC section to a person over in Europe who holds another position in the company in addition to wrting the CMC section.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: